Structural imaging markers for therapeutic trials in Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 13, Issue 4, 2009, Pages 350-352

  Fox, N C ^a   Kennedy, J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; DISEASE MODIFICATION; GENERAL ASPECTS OF DISEASE; GRAY MATTER; HIPPOCAMPUS; HUMAN; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SMALL VESSEL VASCULAR DEMENTIA; STRUCTURAL IMAGING; TEMPORAL LOBE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; RESEARCH DESIGN;

EID: 65249158981     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0040-y     Document Type: Article

References (15)

1. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol. 2002 May;1(1):13-21.
2. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology. 2007 Mar 13;68(11):828-36.
3. Desikan RS, Fischl B, Cabral HJ, Kemper TL, Guttmann CR, Blacker D, Hyman BT, Albert MS, Killiany RJ. MRI measures of temporoparietal regions show differential rates of atrophy during prodromal AD. Neurology. 2008 Sep 9;71(11):819-25
4. Du AT, Schuff N, Kramer JH, Ganzer S, Zhu XP, Jagust WJ, Miller BL, Reed BR, Mungas D, Yaffe K, Chui HC, Weiner MW. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology. 2004 Feb 10;62(3):422-7.
5. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006 Oct;5(10):828-34.
6. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000 Mar;57(3):339-44.
7. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004 Feb 24;62(4):591-600.
8. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005 May 10;64(9):1563-72.
9. Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, Thompson P, Fox NC. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging. 2008 Mar 15.
10. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Toga AW, Jack CR Jr, Schuff N, Weiner MW, Thompson PM; The Alzheimer's Disease Neuroimaging Initiative. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage. 2008 Nov 8.
11. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology. 2005 Jul
12. (1):119-24. 12. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, Rossor MN, Fox NC. Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. J Neurol. 2006 Sep;253(9):1147-53.
13. Smith SM, Rao A, De Stefano N, Jenkinson M, Schott JM, Matthews PM, Fox NC. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage. 2007 Jul 15;36(4):1200-6. Epub 2007 Apr 27.
14. Grundman M and Black R. Clinical trials of Bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's and Dementia. 2008 July; 4(4) Suppl 2:T166
15. Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC. Volumetric MRI and cognitive measures in Alzheimer disease: comparison of markers of progression. J Neurol. 2008 Apr;255(4):567-74.